Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 146Breast Neoplasms 112Prostatic Neoplasms 59Multiple Myeloma 55Neoplasms 54Lung Neoplasms 49Neoplasm Metastasis 42Colorectal Neoplasms 34Ovarian Neoplasms 33Parkinson Disease 4, Autosomal Dominant Lewy Body 31Leukemia, Lymphocytic, Chronic, B-Cell 31Recurrence 26Leukemia, Myeloid, Acute 26Carcinoma, Renal Cell 25Urinary Bladder Neoplasms 24Triple Negative Breast Neoplasms 21Small Cell Lung Carcinoma 21Myasthenia Gravis 21Endometrial Neoplasms 21Carcinoma, Hepatocellular 21Squamous Cell Carcinoma of Head and Neck 20Lymphoma, Large B-Cell, Diffuse 20Melanoma 18Lymphoma, Follicular 18Nasopharyngeal Carcinoma 17Fallopian Tube Neoplasms 16Pancreatic Neoplasms 15Non-Muscle Invasive Bladder Neoplasms 15Brain Neoplasms 15Stomach Neoplasms 14

Interventions

zanidatamab 1tislelizumab 1sitravatinib 1pamiparib 1lenvatinib 1Temozolomide 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Advanced Malignancies × 90 days × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡